GlassScriptPhysician profile
Meera Pradeep
NPI 1346529948
$15,459.75
in general payments reported to CMS, 2019-2025
35 companies · $4,854 in 2025
The $4,854 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,521 · 2022: $2,373 · 2023: $2,683 · 2024: $4,028 · 2025: $4,854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $675.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,890.00 |
| Education | $675.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,893.55 | 2021-2025 | |
| Janssen Biotech, INC. | $1,629.12 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Lilly USA, LLC | $1,448.16 | 2021-2025 | Olumiant, Taltz, Ebglyss |
| Sun Pharmaceutical Industries INC. | $1,174.43 | 2021-2025 | Blu-U, Odomzo, Winlevi |
| Leo Pharma INC. | $1,096.72 | 2021-2025 | Adbry |
| Regeneron Healthcare Solutions, INC. | $1,007.85 | 2021-2025 | Dupixent, Libtayo |
| Incyte Corporation | $868.81 | 2021-2025 | Opzelura, Opzelura |
| Arcutis Biotherapeutics, INC. | $780.50 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $775.70 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $698.36 | 2022-2025 | Sotyktu |
| Pfizer INC. | $686.71 | 2021-2025 | |
| Ucb, INC. | $580.98 | 2021-2025 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $549.57 | 2021-2025 | Nemluvio, Aklief, Epsolay |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $501.18 | 2021-2025 | Siliq, Jublia, Cabtreo |
| Genzyme Corporation | $375.18 | 2021-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $342.20 | 2021-2025 | Otezla, Otezla |
| Journey Medical Corporation | $199.12 | 2022-2025 | |
| Dermavant Sciences, INC. | $88.16 | 2023-2024 | Vtama |
| Botanix Sb INC | $74.03 | 2025 | Sofdra |
| Genentech USA, INC. | $73.26 | 2021-2022 | |
| Fidia Pharma USA INC. | $70.47 | 2024-2025 | |
| Almirall LLC | $69.88 | 2022-2025 | Klisyri, Seysara |
| Organon LLC | $67.76 | 2025 | Vtama, Nexplanon |
| Mayne Pharma Commercial LLC | $64.96 | 2023-2025 | |
| Epi Health, LLC | $54.52 | 2021-2022 | |
| Celgene Corporation | $51.51 | 2024 | Sotyktu |
| Vyne Pharmaceuticals INC. | $47.75 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.28 | 2022-2025 | Spevigo |
| Verrica Pharmaceuticals INC. | $28.08 | 2023-2024 | Ycanth |
| Helsinn Therapeutics (U.S.), INC. | $27.29 | 2022-2024 | Valchlor |
| Nabriva Therapeutics, Plc | $26.93 | 2022 | |
| Polarityte, INC. | $17.20 | 2021 | |
| Fresenius Kabi USA, LLC | $15.00 | 2023 | |
| Biofrontera INC. | $15.00 | 2021 | |
| Kyowa Kirin, INC. | $14.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meera Pradeep listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.